To determine the efficacy of high dose folic acid supplementation for prevention of pre-eclampsia in women with at least one risk factor: pre-existing hypertension, prepregnancy diabetes (type 1 or 2), twin pregnancy, pre-eclampsia in a previous pregnancy, or body mass index ≥35.
Introduction
Pre-eclampsia is a serious medical condition, affecting about 3-5% of pregnancies, 1 2 accounting for more than 35 000 maternal deaths annually worldwide and an important factor in maternal morbidity. 1 3 4 Preeclampsia affects multiple organ systems and leads to an increased risk of severe complications in pregnancy. 5 Since delivery of the placenta is the only known cure, pre-eclampsia is a leading cause of indicated preterm delivery, 1 2 perinatal morbidity, mortality, and long term disability. 6 7 Epidemiological studies of the association between folic acid supplementation and the incidence of pre-eclampsia have shown a potential protective effect, 9 although findings have been inconsistent. [8] [9] [10] [11] [12] [13] [14] In a randomised trial of supplementation with a multivitamin containing 0.8 mg folic acid and hypertension in pregnancy in a high risk population of women positive for antibodies to HIV, a 38% reduction was observed in the primary composite outcome of gestational hypertension (including pre-eclampsia or eclampsia) in the intervention group compared with placebo group. 15 Other forms of folate, including 5-methyltetrahydrofolate, have been investigated with similar results, 16 whereas folic acid antagonists have shown the opposite effect, increasing the risk of preeclampsia. 17 Based on large randomised trials, 18 19 supplementation of folic acid to prevent neural tube defects has been recommended worldwide during the preconception period and the first trimester of pregnancy. Recommended doi: 10.1136/bmj.k3478 | BMJ 2018;362:k3478 | the bmj doses are 4.0-5.0 mg daily up to 12 weeks' gestation for women at high risk of having an affected fetus, and 0.4-1.0 mg daily for women at low risk. [20] [21] [22] Although the neural tube closes in the first trimester, preeclampsia is a two stage disorder, with the first stage occurring in the late first trimester (after eight weeks) and the second stage occurring in the third trimester. Supplementation of high doses of folic acid in early gestation may work at both stages of pre-eclampsia development, and a larger dose in the late first or early second trimester (between eight and 16 week's gestation) during the peak period of placental growth and development may be most effective in preventing pre-eclampsia. Findings from the Ottawa and Kingston (OaK) Birth Cohort suggested a 60% reduction in risk of pre-eclampsia and a dose-response association between folic acid and risk of pre-eclampsia in women with identified risk factors. 9 23 A high daily dose (4.0 mg) of folic acid might be needed for these women because they may have placental, endothelial, and metabolic defects (including those of folate metabolism) leading to an increased risk of developing pre-eclampsia. Previous studies have been observational in nature and thus warranted a large randomised controlled trial. The current study, the Folic Acid Clinical Trial (FACT), was designed and conducted to evaluate the effect of daily supplementation with 4.0 mg folic acid beyond the first trimester on the risk of developing preeclampsia among pregnant women at high risk for this condition.
Methods
Trial design and study population FACT was a randomised, double blinded, placebo controlled, phase III, international multicentre trial carried out at 70 high risk obstetric referral centres covering diverse populations in Canada, Argentina, Australia, Jamaica, and the United Kingdom (see supplementary table S1).
We considered pregnant women to be eligible for participation in the trial if they were between eight and 16 completed weeks of gestation with a confirmed viable fetus and at least one of the following risk factors for pre-eclampsia: pre-existing hypertension, prepregnancy diabetes (type 1 or 2), twin pregnancy, pre-eclampsia in a previous pregnancy, or body mass index (BMI) ≥35 kg/m 2 . Documentation of BMI measured (height and weight) between three months before pregnancy and up to the time of randomisation was required as part of study eligibility. We excluded women if they had a known fetal anomaly or fetal death, a history of maternal medical complications (including renal disease with altered renal function), epilepsy, cancer, or current use of folic acid antagonists, illicit drug or alcohol misuse (≥2 drinks daily) during current pregnancy, known hypersensitivity to folic acid, multiple pregnancy, previous participation in this trial, or a history or presence of any important disease or condition that would preclude the use of high dose (up to 5.1 mg daily) folic acid.
Participant recruitment and randomisation
The purpose and requirements of the trial were explained to eligible women, and after written informed consent, we randomised participants to either folic acid or placebo.
The Methods Centre at Ottawa Hospital Research Institute implemented randomisation using a web based randomisation platform that generated a unique randomisation ID. Randomisation used variable permuted blocks of four and six with stratification by centre. Study data were entered into the web based platform at each site. Study treatment was centrally prepared, pre-labelled with unique study IDs and provided to each site.
The trial intervention consisted of 4.0 mg folic acid or placebo, taken as four 1.0 mg tablets once daily, from randomisation (8-16 completed weeks of gestation) until delivery. Participants could continue taking prenatal vitamins or low dose folic acid supplements containing up to 1.1 mg of folic acid. The folic acid and placebo tablets had no taste and an identical external appearance, thereby masking participants to their treatment group. The data coordinating centre managed treatment allocation, and all participants, site investigators, coordinators and other research staff, and members of the trial coordinating centre were blinded to treatment allocation after randomisation. No unmasking occurred during the trial.
No benefit found for high dose folic acid supplementation beyond the first trimester for the prevention of pre-eclampsia or related maternal and neonatal adverse outcomes. Frequency and duration of follow-up A total of four follow-up visits occurred at 24-26 completed weeks of gestation, 34-36 completed weeks of gestation, after delivery, and 42 days post partum. At the initial study visit, information was collected on personal characteristics and maternal medical history. At study visits we carried out a physical examination (blood pressure, weight, urinalysis (urine dipstick), and fetal wellbeing) and documented concomitant drugs. Laboratory values were obtained at delivery, and maternal and neonatal information were collected from hospital records. At each visit we assessed and documented adverse events. Adherence to the study treatment was determined with the aid of a drug diary and pill counts. We asked participants to return their study treatment bottles at each visit. Compliance was measured as the percentage of pills remaining in the returned bottles, and participants completed the Dietary Folate Equivalent Screener (Block Food Frequency Questionnaire: www.nutritionquest.com) at randomisation and at 24-26 completed weeks of gestation.
Clinical significance

Primary outcome
The primary outcome was pre-eclampsia, defined using the accepted definition at the time the trial commenced: diastolic blood pressure ≥90 mm Hg on two occasions four hours or more apart and proteinuria (more than ++ on dipstick, or urinary protein ≥300 mg in 24 hour urine collection, or random protein:creatinine ratio ≥30 mg protein/mmol) in women at 20 weeks of gestation or greater, or diagnosis of HELLP syndrome (haemolysis, elevated liver enzymes, low platelets) or superimposed pre-eclampsia (history of pre-existing hypertension diagnosed before pregnancy or before 20 weeks' gestation with new proteinuria). 2 The primary outcome (the trial protocol definition of pre-eclampsia) was adjudicated based on the consensus opinion of three investigators (MW, LG, and SWW). Adjudication was conducted before any statistical data analysis, masked to treatment group, country, and site. We excluded women from the primary outcome analysis who experienced a miscarriage, experienced early intrauterine fetal death (20-24 weeks of gestation), or withdrew consent.
Secondary outcomes
Prespecified secondary outcomes included maternal death, severe pre-eclampsia (pre-eclampsia with convulsion or HELLP or delivery <34 completed weeks of gestation), placental abruption, preterm delivery (<37 completed weeks of gestation), premature rupture of membranes, antenatal inpatient length of stay, intrauterine growth restriction (<3rd centile), perinatal mortality, spontaneous abortion (miscarriage), stillbirth, neonatal mortality, neonatal morbidity (retinopathy of prematurity, periventricular leukomalacia, early onset sepsis, necrotising enterocolitis, intraventricular haemorrhage, ventilation, need for oxygen at 28 days), and length of stay in neonatal intensive care unit.
Adverse events reporting and safety monitoring
An independent data safety and monitoring board oversaw the safety of the trial. We collected and reviewed all adverse events from randomisation to 42 days post partum. An adverse event was defined as an untoward medical occurrence in a participant that may or may not have had a causal relation to the study treatment. A serious adverse event was defined as any untoward medical occurrence that resulted in maternal, fetal, or neonatal death; was life threatening; required prolonged hospital stay; caused persistent or major disability, incapacity, or congenital anomaly; or was deemed an important medical event. No safety issues were detected after the independent data safety and monitoring board's review.
Statistical analysis
On the basis of data from high risk pregnant women, 24 we originally estimated that a sample of 3656 pregnant women was needed to detect a 30% reduction of preeclampsia from 12.0% to 8.4% (90% power, two sided type I error 0.05) and to allow for up to 30% non-adherence, withdrawal, loss to follow-up, or other unanticipated events. However, owing to budget limitations, and because our follow-up rate was better than expected, we recalculated the sample size to 2464 women, which retained a study power of greater than 80% and still allowed for up to 10% loss to follow-up and withdrawal. In September 2015 the trial steering committee approved the sample size adjustment, and we notified the independent data safety and monitoring board. Based on the recruitment rate at the time of these meetings, a total new anticipated recruitment target of 2464 participants would be achieved by November, and as a result no interim analysis of outcomes would be conducted.
The analysis was carried out on an intention to treat basis. We first compared the baseline characteristics, compliance, folic acid intake from other sources, and supplementation with aspirin or calcium, or both, between intervention and placebo groups. The outcomes between these groups were then compared, using χ 2 tests for the incidence of pre-eclampsia and categorical secondary outcomes and t tests for the means of continuously distributed secondary outcomes. Multiple log binomial regression was conducted on the primary outcome to adjust for potential confounding by parity, age, cigarette smoking, and other important prognostic factors identified a priori. A generalised estimating equation model was used to account for the correlation between two fetuses or infants from the same pregnancy in analyses of neonatal outcomes. Treatment effects are expressed as relative risk with 95% confidence intervals. No allowance for multiplicity was made for secondary outcomes. All statistical analyses were performed using Statistical Analysis System, version 9.1 (SAS Institute, Cary, NC).
Patient involvement
Although we did not actively seek patient engagement in the development of this protocol, physicians' input was provided through a survey, suggesting that their patient population would be interested in the trial and we sought their advice on best practices to roll out the trial. A steering committee of international content experts with varied expertise provided input in the development of the protocol, study outcomes, and trial procedures. The committee also examined how to minimise the impact on trial participants, as such, trial follow-up visits were coordinated with routine antenatal care visits. Patients were not involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment or implementation of the study. Patients were not asked to advise on interpretation or writing up of the results. Participants are acknowledged and thanked for their contribution and participation in this important trial. A dissemination strategy has been developed to work closely with stakeholders and knowledge users to facilitate transfer of the findings to relevant users, including patients and clinicians.
Results
Characteristics of participants
Between April 2011 and November 2015, 6499 pregnant women were screened and 2464 of these women were enrolled into the trial, 1228 of whom were randomised to folic acid and 1236 to placebo. After excluding women who experienced miscarriage (n=37), experienced early intrauterine fetal death (20-24 weeks of gestation, n=12), had no primary outcome data available (n=28), or withdrew consent before outcome ascertainment (n=85), primary outcome data were available for 2301 women (93.4%) (1144 in the folic acid group and 1157 in the placebo group) (fig 1) , representing a follow-up rate of 96.5%. A total of 485 women across both groups discontinued study treatment but remained in the trial and provided data for primary and secondary outcomes.
The distribution of baseline and pregnancy characteristics was similar between the two groups. More than 80% of pregnant women in both groups reported taking supplemental folic acid or folic acid containing vitamins. Among the 1941 (78.8%) women who returned study treatment bottles, 1465 (75.5%) took at least 75% of their pills, confirming a high compliance rate (table 1). Analyses of blood samples from 50 participants (19 in folic acid group and 31 in placebo group) in Canadian centres indicated that serum folate was substantially higher in the folic acid group (mean 260.1 v 77.8 nmol/L, P=0.008) and red blood cell folate levels were similar (2700 v 2680 nmol/L, P=0.88).
No statistically significant differences were observed in reported adverse events or severe adverse events between the two groups (see supplementary table S2 ). The effect did not differ by country (see supplementary  table S4 ).
Discussion
The results of our international randomised controlled multicentre trial did not show evidence that supplementation with high dose folic acid (4.0-5.1 mg) initiated between eight and 16 completed weeks of gestation and continued until delivery prevents preeclampsia in at risk women. We adjusted analyses for potential confounders by parity, maternal age, and cigarette smoking and confirmed there was no effect of folic acid on the prevention of pre-eclampsia. When we explored the effect of high dose folic acid on risk of pre-eclampsia by country, no difference in effect was observed.
Comparison with other studies Supplementation with folic acid during pregnancy is now common in many countries of the world. In our previous cohort study, of 2951 pregnant women recruited between 2002 and 2005 in Ottawa and Kingston, Canada, 2713 (91.9%) took folic acid supplements during pregnancy, 9 and of women who used folic acid supplementation, only 544 (20.0%) discontinued in the third trimester, whereas 447 (16.5%) used more than 2.0 mg/day. 9 Similar patterns were observed in our trial population, with more than 80% of women taking supplemental folic acid. Supplementation with high dose folic acid (usually 4.0-5.0 mg daily) in pregnant women has already become widespread beyond the first trimester. 9 13 14 25-29 Anecdotal evidence suggests that supplementation with high dose folic acid is occurring outside the recommendations for use only in early pregnancy for prevention of neural tube defects, even though the most recent Cochrane review of folic acid in Participants who completed study and were analysed for primary outcome (n= )
Participants who completed study and were analysed for primary outcome (n= ) pregnancy for maternal health outcomes was not able to report on pre-eclampsia owing to lack of data from clinical trials. 30 Caution should always be exercised in recommending treatments before thorough evaluation has been completed, including follow-up of offspring when possible.
Strengths and limitations of this study FACT has several notable strengths. Firstly, it was designed to be as conclusive as possible in a rigorous, large, randomised, double blinded, placebo controlled, phase III, international and multicentre trial. The trial conduct adhered to strong research and ethical principles, high data completeness, and compliance by participants. The follow-up rate was greater than 95% and compliance to the study treatment was greater than 75% in most of the study population.
Steps were taken to ensure the lowest possible risk of bias, although we did not investigate baseline folic acid values, compliance, and levels during pregnancy in subgroups of high risk factors for pre-eclampsia.
A clear advantage of our trial is the robust randomised design, although some limitations are present. Preeclampsia has a complex heterogenous aetiology despite characteristic phenotypic outcomes. 31 In the original trial protocol we clearly laid out the criteria for the definition of pre-eclampsia and used this for case adjudication. These criteria have remained consistent with NICE guidelines for the diagnosis of pre-eclampsia, although there have been revisions to the definition of pre-eclampsia in other settings, including Canada. 32 As a result, using the revised guidelines, there may be additional women in the study population who would have a diagnosis of preeclampsia; however, owing to the randomised design this would be balanced across the treatment groups and not anticipated to affect the association between folic acid and pre-eclampsia, regardless of definition. Finally, power was reduced from 90% to 80%, but because we found no evidence in favour of the study intervention, even an increase of power would have been unlikely to find a treatment effect. NICU=neonatal intensive care unit. *Generalised estimating equation was used to account for correlation between two fetuses or infants from the same pregnancy. Composite outcome included any of retinopathy of prematurity, periventricular leukomalacia, early onset sepsis, necrotising enterocolitis, intraventricular haemorrhage, ventilation, need for oxygen at 28 days, and NICU admission. †Mean (SD). ‡Mean difference (95% CI).
Conclusion and policy implications
Future directions for this research include exploration of the increased risk of pre-eclampsia in mothers carrying twins and using high dose folic acid, and the potential protective effect of folic acid on perinatal death warrants ongoing study. Perhaps most importantly, FACT provides a unique opportunity to follow the participants and their offspring to study the effects of high dose folic acid during prenatal development on long term maternal and child health, given the potential epigenetic effects of folic acid. Funding has been obtained to follow these FACT offspring for mortality and neurocognitive development through to six years of age. Our well powered trial did not find benefit for high dose folic acid supplementation beyond the first trimester for the prevention of pre-eclampsia or related maternal and neonatal adverse outcomes. The trial deals with an important public health issue: the lack of demonstrated benefit of high dose folic acid supplementation beyond the first trimester for women at high risk of developing pre-eclampsia indicates that high dose recommendation should now cease, and the search for an effective and acceptable strategy to prevent pre-eclampsia must continue.
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